Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed. This open-label, phase 3 trial evalua...

Celý popis

Podrobná bibliografia

Vydané v:	Clinical infectious diseases
Hlavní autori:	Goswami, Jaya, Cardona, Jose F, Caso, Jorge, Hsu, Denise C, Simorellis, Alana K, Wilson, Lauren, Dhar, Rakesh, Wang, Xiaowei, Kapoor, Archana, Collins, Avi, Righi, Vinicius, Lan, Lan, Du, Jiejun, Zhou, Honghong, Stoszek, Sonia K, Shaw, Christine A, Reuter, Caroline, Wilson, Eleanor, Das, Rituparna
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 23.09.2025
Predmet:	mRNA RSV vaccine revaccination respiratory syncytial virus safety immunogenicity
ISSN:	1537-6591, 1537-6591
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!